Moore Capital Management’s ProKidney PROK Stock Holding History

Moore Capital Management’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-26,500	Closed	-$239K	–	620
2022 Q3	$239K	Sell	26,500 -223,500	-89%	-$1.94M	0.01%	448
2022 Q2	$2.49M	Hold	250,000	–	–	0.07%	289
2022 Q1	$2.47M	Hold	250,000	–	–	0.06%	330
2021 Q4	$2.48M	Hold	250,000	–	–	0.05%	354
2021 Q3	$2.45M	Hold	250,000	–	–	0.04%	408
2021 Q2	$2.53M	Buy	+250,000	New	+$2.53M	0.04%	407

Other funds holding PROK

SCG

Social Capital Group Menlo Park, California $5.16M AUM 66.85% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Brown University Providence, Rhode Island $112M AUM 3.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Moore Capital Management's PROK Position: Q4 2022 in Review

Moore Capital Management sold out of ProKidney (PROK) in Q4 2022, closing a stake of 26,500 shares — an estimated $239K sold.

Moore Capital Management first reported a position in PROK in Q2 2021 and held it in 6 quarters. The position peaked at $2.53M in Q2 2021. 27 funds tracked by Wall St. Rank hold PROK as of Q4 2022.

Moore Capital Management reported no remaining ProKidney position as of Q4 2022 after selling out during the quarter.
Moore Capital Management sold 26,500 ProKidney shares in Q4 2022, an estimated $239K.
Moore Capital Management first reported a position in ProKidney in Q2 2021 and held it in 6 quarters.
Moore Capital Management's ProKidney position peaked at $2.53M in Q2 2021.
27 funds tracked by Wall St. Rank held ProKidney as of Q4 2022.

Based on Moore Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.